Open Calls for Input and Feedback


Listed are current opportunities for patient groups, clinician groups, drug plans, and cancer agencies to provide input or feedback on drugs being assessed within the reimbursement review process.

At CADTH, input is information, insight, or advice given to CADTH to contribute to a review. Feedback is a response to a prepared proposal, review report, or draft recommendation.

Draft Recommendations

Lorbrena (lorlatinib)

Therapeutic Area: ALK-positive locally advanced or metastatic non-small cell lung
Draft recommendations posted for stakeholder feedback: December 02, 2021
End of feedback period: December 16, 2021
Draft Recommendation

Submit Feedback

 

Padcev (enfortumab vedotin)

Therapeutic Area: Locally advanced or metastatic urothelial carcinoma
Draft recommendations posted for stakeholder feedback: December 02, 2021
End of feedback period: December 16, 2021
Draft Recommendation

Submit Feedback

 

Emgality (galcanezumab)

Therapeutic Area: Prevention of migraine
Draft recommendations posted for stakeholder feedback: November 18, 2021
End of feedback period: December 2, 2021
Draft Recommendation

Submit Feedback

 

Myinfla (colchicine)

Therapeutic Area: Atherothrombotic events in coronary artery disease
Draft recommendations posted for stakeholder feedback: November 18, 2021
End of feedback period: December 2, 2021
Draft Recommendation

Submit Feedback

 

Ngenla (somatrogon)

Therapeutic Area: Growth hormone deficiency
Draft recommendations posted for stakeholder feedback: November 18, 2021
End of feedback period: December 2, 2021
Draft Recommendation

Submit Feedback

 

Opsynvi (macitentan and tadalafil)

Therapeutic Area: Pulmonary arterial hypertension
Draft recommendations posted for stakeholder feedback: November 18, 2021
End of feedback period: December 2, 2021
Draft Recommendation

Submit Feedback

 

Open Calls for Patient and Clinician Input

Therapeutic Area
Therapeutic Area: Lambert-Eaton Myasthenic Syndrome, adults
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: Diffuse large B-cell lymphoma (DLBCL)
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed: